Hyderabad, Feb 18 (.) BioAsia 2026, the 23rd edition of Asia’s premier life sciences and health-tech forum, concluded here on Wednesday with unprecedented success, firmly cementing Telangana’s position as a global hub for life sciences, TechBio and innovation-led growth.
The two-day event recorded its highest-ever participation, with over 4,500 delegates and visitors from India and abroad, including global leaders, policymakers, scientists, investors and entrepreneurs.
BioAsia 2026 facilitated more than 4,000 high-impact B2B meetings, unlocking new collaborations, partnerships and investment opportunities across the life sciences ecosystem.
The closing ceremony was preceded by a fireside chat with Industries and Commerce Minister D Sridhar Babu, who outlined the State’s roadmap under the Rising Telangana Vision 2047 to transform Telangana into a USD 3 trillion economy.
The discussion highlighted policy direction, industrial strategy and the role of innovation in achieving long-term economic growth.
A major highlight of the event was the strong focus on startups and innovation. More than 120 startups were shortlisted by an eminent jury, of which over 40 showcased disruptive solutions across MedTech, medical devices, biopharma, cell and gene therapy, AI and ML, nutraceuticals and biomarkers.
Five startups — Achala Health Services Private Limited, Exquinz Life Sciences Pvt Ltd, Helex, Natural Solutions & Nutraceuticals Pvt Ltd, and Sree Guravey Life Sciences OPC Pvt Ltd — received the BioAsia 2026 Innovation Awards for their breakthrough contributions.
Addressing the gathering, Minister Sridhar Babu described BioAsia 2026 as the most successful edition so far, highlighting Telangana’s leadership in integrating AI, automation and advanced biology.
He said the State is committed to building a future-ready ecosystem through initiatives such as the Next Generation Life Sciences Policy 2026–30, aimed at attracting global capital, talent and expertise while translating scientific breakthroughs into real-world healthcare solutions.
Special Chief Secretary Sanjay Kumar said BioAsia has emerged as a powerful platform for cross-border collaboration, enabling startups, researchers and industry leaders to drive innovation in advanced therapeutics, digital health, precision medicine, AI-driven drug discovery and CRDMO solutions.
He said Telangana’s policy foresight, infrastructure and regulatory support are creating a globally competitive life sciences ecosystem.
Telangana Life Sciences CEO Shakti M. Nagappan said BioAsia 2026 recorded the highest number of delegates and discussions in the event’s history, adding that the partnerships and collaborations forged would act as a catalyst for the next phase of innovation-led growth in the State.
The event featured an impressive lineup of global speakers, including Prof. Bruce L. Levine (University of Pennsylvania), Dr Howard Y. Chang (Amgen, USA), Pushmeet Kohli (Google DeepMind, UK), and Madeleine Roach (Sanofi, France), who shared insights on AI-driven biomedical discovery, next-generation biologics, CRDMO innovation and resilient healthcare systems.
The final day saw four high-level panel discussions focusing on innovation-first Global Capability Centres (GCCs), translating R&D into patient impact, India’s transition from manufacturing to innovation-led leadership, and financing TechBio and deep-tech manufacturing.
As BioAsia 2026 drew to a close, it reaffirmed its role as a bridge between innovation and enterprise, strengthening international engagement and investor confidence. With landmark partnerships and growing global interest, anticipation has already begun building for BioAsia 2027, expected to further shape the future of global healthcare and life sciences.
. VV .
